ImmuSAFE

Protein Array

CodeProduct Name
39508H

Sengenics ImmuSAFE COVID+ Array Kit

39508H-600

Sengenics ImmuSAFE COVID+ Array Kit Package (600 Samples)

39508H-1200

Sengenics ImmuSAFE COVID+ Array Kit Package (1200 Samples)

Order on Science Exchange

Product Highlights

Product Description

Measure three critical components of COVID-19 from a single sample on one chip:

  • Antibodies to N or S
  • Neutralising antibodies to S
  • Autoantibodies implicated in COVID-19 severity

Contains multiple SARS-CoV-2 specific domains (Nucleocapsid and Spike proteins) including full-length and numerous truncated versions and IFN, TNF, ANA etc.

Specifications

Product Namexx
Product Name

Sengenics ImmuSAFE COVID+ Array

Platform

Sengenics' proprietary Streptavidin-coated hydrogel surface chemistry provides an aqueous environment, preserving native protein folding and function. Due to the binding of the biotinylated BCCP folding marker with Streptavidin, proteins are oriented consistently with a single attachment point and are also distal (50Å) to the surface further enhancing their capability to fully interact with target biomolecules. KREX proteins behave as if they are in free solution, with full capability to interact at high specificity with autoantibodies and antibodies

Number of arrays

24 arrays (24 samples) per slide

Sample type

Human serum/plasma
*please contact us for requirements of other types of samples

Delivery Lead Time

(39508H) 2 weeks

System CompatibilityAny open-format microarray scanner
Storage conditionsStore for up to 12 months at -20°c
Shipping

Frozen shipment in dry ice

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389